We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications ( KMT2A -PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of KMT2A -PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with KMT2A -PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with KMT2A -PTD ≥1% before HSCT had a slower decrease of KMT2A -PTD after HID HSCT. Patients with KMT2A -PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%–66.5%) at 2 years after HSCT than those with KMT2A -PTD <1% (7.5%, 95% CI: 0.3%–14.7%, P = .010). In multivariable analysis, KMT2A -PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22–19.59; P = .025). Thus, pre-transplantation levels of KMT2A -PTD could predict relapse in AML patients following HID HSCT.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: